Hangzhou Sumgen Biotech
As of the edition of 20 October 2026, Hangzhou Sumgen Biotech runs 5 drugs; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Active | 4 |
| Stopped | 1 |
| Total | 5 |
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| CD47 Leukocyte surface antigen CD47 | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Hangzhou Sumgen Biotech needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Immune system: 6 trials led
- Blood and lymph: 4 trials led
- Cancer: 4 trials led